Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

ASFaVIP Understanding Performance Characteristics of Live Attenuated Vaccines for the Prevention and Control of African Swine Fever in Wild Boar and Domestic Pigs

Coordinator
Friedrich Loeffler Institut - Bundesforschungsinstitut Fuer Tiergesundheit, Germany
Runs
1 January 2024 to 30 June 2027
Status
Running
EU funding
€6.1m
Total cost
€6.1m
Partners
12 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101136676

What the project is doing

In the project's own words, from its summary on CORDIS.

African swine fever (ASF) has recently transformed from an exotic disease to a panzootic threat to domestic and wild suids world-wide. Europe is currently facing different scenarios with front and point introductions, affected wild boar and domestic pig populations, epidemic and endemic situations. While our traditional prevention and control strategies work well with industrial pig farms, we quickly reach our limits when we have to control the disease in the abundant wild boar population or in regions with a majority of backyard farms.

To turn the tide and to safeguard animal health, vaccines, especially oral vaccines for wild boar, could be the missing tool. There has been considerable progress in vaccine development and while we should continue to look for alternative approaches, we must now also dare to test the promising candidates beyond simple proof-of-concept studies. Only in this way can we generate the data base for benefit-risk analysis of whether and how current generation vaccines could be employed.

Along these lines, this project sets out to test the vaccine candidate ""ASFV-G-ΔI177L"" in safety and efficacy tests after oral and intramuscular application as prescribed by international guidelines. This vaccine candidate has shown safety and very good protection under laboratory conditions and has been applied in the field in Vietnam. As a backup option, other promising candidates, “ASFV-G-ΔMGF” and “ASFV-G-Δ9GL/UK, will be tested in initial comparative trials.

Accompanying the prescribed tests, our interdisciplinary consortium will characterize the protective immune responses, target the optimization of oral immunization and model tailored vaccination strategies. The data body generated in this project is crucial for benefit-risk-assessments at the level of all authorities entrusted with licensure and deployment of ASF vaccines and for this reason, relevant stakeholders will be involved from the start to guarantee full exploitation of our data.""

Who is involved

OrganisationCityCountryRole
Friedrich Loeffler Institut - Bundesforschungsinstitut Fuer TiergesundheitGreifswald-Insel RiemsGermanyCoordinator
SciensanoElseneBelgiumParticipant
Eidgenoessisches Departement Des InnernBernSwitzerlandAssociatedpartner
Dorsch JulianBerlinGermanyParticipant
Helmholtz-Zentrum Fur Umweltforschung GmbH - UfzLeipzigGermanyParticipant
Statens Serum InstitutKobenhavn SDenmarkParticipant
Universidad De Castilla - La ManchaCiudad RealSpainParticipant
Zoetis Manufacturing & Research Spain SLVall De Bianya GironaSpainAssociatedpartner
Association Internationale De Standardisation Biologique Pour L'europe(iabs-Eu)LyonFranceParticipant
Partikas Drosibas, Dzivnieku Veselibas Un Vides Zinatniskais InstitutsbiorRigaLatviaParticipant
Stichting Wageningen ResearchWageningenNetherlandsParticipant
United States Department of Agriculture - Plains AreaOrient PointUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI